Abstract
One hundred and six patients with advanced adenocarcinoma and large cell carcinoma of the lung with no prior chemotherapy were entered in a prospectively randomized trial comparing cyclophosphamide, doxorubicin, and cisplatin versus methotrexate, doxorubicin, cyclophosphamide, and lomustine. The two regimens resulted in nearly identical regression probabilities (36% vs 34%), distributions of time to progression, and survival distributions. The major toxic effects from both regimens consisted primarily of myelosuppression and nausea and vomiting, with severe vomiting occurring more frequently in patients treated with cyclophosphamide, doxorubicin, and cisplatin (43% vs 19%).
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Cisplatin / adverse effects
-
Cisplatin / therapeutic use
-
Clinical Trials as Topic
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Lomustine / administration & dosage
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Nausea / chemically induced
-
Probability
-
Prospective Studies
-
Vomiting / chemically induced
Substances
-
Lomustine
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Methotrexate
Supplementary concepts
-
CISCA protocol
-
MACC combination